
Antidepressant Risk/Benefit: Fish Oil Versus Placebo
Could fish oil replace antidepressants as a first-line pill for depression?
Could fish oil replace antidepressants as a first-line pill for depression? New data from placebo research invite this consideration (just when the magnitude of antidepressant benefit is
The AMA Code of Medical Ethics states that use of a placebo without patients’ knowledge undermines trust. Accordingly, use of a placebo without deception would not be unethical.2 But could that help anyone? Clearly yes, say multiple studies of open-label placebo (OLP)3, due to the brain’s Bayesian approach to symptoms.4
For example: in a 3-week trial in irritable bowel syndrome (IBS), patients receiving OLP were told the pills were inactive (ie, “inert”), like a sugar pill that contained no medication. The 15-minute semi-scripted explanation included mention that the placebo effect is powerful; that the body can automatically respond to taking placebo pills (like Pavlov's dogs who salivated when they heard a bell), and that a positive attitude helps but is not necessary.5
Remarkably, roughly twice as many patients in the OLP group experienced “adequate pain relief” compared with those on the wait list (49% versus 23% at 11 days; 59% versus 35% at 3 weeks). A 2021 study replicated and advanced these findings.6
Rethinking Antidepressants
Antidepressants are better than placebos—by a small margin, with an average effect size of 0.3 across 7 meta-analyses.7 Antidepressant percentage-response rates are also superior to placebo by a small margin, narrowed by placebo response rates around 35% to 40%.8 In other words, placebos are markedly effective in depression (less so in treatment-resistant cases, where the placebo response rate is around 20%9). Thus prescribers must be careful not to undermine antidepressants’ placebo effect by inviting doubt about benefits relative to risks.10
Consider severe withdrawal symptoms on discontinuation, for example: incidence estimates range from 1% to 2%, per a respected academic11, to 50% in an oft-cited survey of patient experience12—an unfortunately broad range. Nevertheless, making clear to patients even a 1% to 2% chance of life-limiting symptoms (cannot take care of family, work, or go to school) could seriously interfere with positive expectations.
This leaves practitioners balancing 2 opposing goals and ethical principles: fully informed consent (autonomy), versus maximizing benefit (beneficence).10 Trying to narrow the divide between psychiatry and its critics, I presented this dilemma in
There is no conflict between being honest about the marginal efficacy of antidepressants and maximizing the placebo effect. The supposed conflict can easily be resolved by — talking up a placebo! As long as you’re going to fabulate, do it with a relatively harmless drug.
Think about that for a minute, minus the little jab about “fabulating.” Is there a relatively harmless pill that could be offered as an OLP for depression? Better if the pill actually had some evidence for efficacy, as then practitioners would not have to be so careful to avoid deception, as they would with a true OLP.
Internists recommend aspirin as a treatment for some kinds of pain, knowing that most of any positive effect it produces is due to an expectation of benefit they have instilled more than a physiologic action.13 Could we recommend fish oil in like fashion?
Omega-3s for Depression: Not Quite a Placebo
Since 2011, there have been 3 meta-analyses of randomized trials of omega-3s for the treatment of depression. One attributed positive results to publication bias.14 Two found that doses less than 750 to 1000 mg of EPA (in a form that is at least 60% EPA relative to DHA) were not better than placebo.15,16
Antidepressants also have mixed results when unpublished negative results are included.17 Thus prescribers need not change their general description of alternatives when including fish oil. For example (holding one’s hands like scales of judgement): “Option A has a 1-in-3 chance of helping, with no adverse effects and no risks. Option B has about a 1-in-2 chance of helping, but a 1-in-100 to 1-in-50 chance of causing troublesome withdrawal effects when you stop it, such that you would be unable to work, go to school, or support your family. Which would you like to try first?”
A Patient Decision Aid for Depression
These options should be preceded by consideration of a broader array of treatment approaches, as in a patient decision aid (PDA). PDAs are handouts and videos designed to help patients join in shared decision-making. PDAs often read like reports from the Intergovernmental Panel on Climate Change, weakened by the need for complete consensus among authors. For example, Ottawa Hospital hosts a
Concluding Thoughts
MIA reader Altostrata suggested that apparent ethical conflicts between the goals of autonomy and beneficence can easily be resolved by talking up a harmless placebo. Fish oil meets the “harmless” criterion, so could be used as an open-label placebo. Better yet, omega-3s have at least mixed evidence for efficacy greater than placebo. But will patients really consider it as an alternative to a pharmaceutical antidepressant?
That depends on how the risks of antidepressants are presented, which depends on your working estimate of risks such as withdrawal and post-SSRI-sexual dysfunction. Controversy over these sequelae has devolved into for-or-against-antidepressant camps, such that whatever incidence rates I cite (from 1% to 50%), you are likely to think antidepressant risks are either seriously underestimated or dangerously overstated.
Unfortunately, I fear I have not moved the needle at all on antidepressant prescription, an admitted goal. What we really need is more data on the incidence of serious antidepressant risks. In the interim, thank you for considering the line of thought offered here.
Dr Phelps is research editor at the Psychopharmacology Institute; emeritus faculty at Samaritan Mental Health in Corvallis, Oregon; and founder of
Acknowledgment: The author would like to thank Altostrata for her thoughtful comment, and Mad in America for presenting his
References
1. Pigott HE, Kim T, Xu C, et al.
2. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F.
3. Kaptchuk TJ, Hemond CC, Miller FG.
4. Ongaro G, Kaptchuk TJ.
5. Kaptchuk TJ, Friedlander E, Kelley JM, et al.
6. Lembo A, Kelley JM, Nee J, et al.
7. Munkholm K, Paludan-Müller AS, Boesen K.
8. Furukawa TA, Cipriani A, Atkinson LZ, et al.
9. Jones BD, Razza LB, Weissman CR, et al.
10. Annoni M, Miller FG.
11. Rashad W, Thase ME. Top 10 drug combinations in MDD - interview with Prof. Michael E. Thase. December 1, 2020. Accessed December 18, 2023.
12. Davies J, Read J.
13. Tilburt JC, Emanuel EJ, Kaptchuk TJ, et al.
14. Bloch MH, Hannestad J.
15. Sublette ME, Ellis SP, Geant AL, Mann JJ.
16. Liao Y, Xie B, Zhang H, et al.
17. Turner EH, Matthews AM, Linardatos E, et al.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.